Effects of granulocyte‐macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high‐dose chemotherapy

@article{Hussein1995EffectsOG,
  title={Effects of granulocyte‐macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high‐dose chemotherapy},
  author={Atif Mahmoud Hussein and Maureen Ross and James J. Vredenburgh and Barry R. Meisenberg and Vera H{\'a}rs and Colleen J. Gilbert and William P. Petros and David Coniglio and Joanne Kurtzberg and Peter Rubin and William P. Peters},
  journal={European Journal of Haematology},
  year={1995},
  volume={55}
}
Abstract: Peripheral blood progenitor cells (PBPCs) were collected without prior association with chemotherapy but after the administration of granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) produced in Chinese hamster ovary cells (CHO‐GM, regramostim), Escherichia coli (E. coli‐GM, molgramostim), or yeast (Yeast‐GM, sargramostim) and used in conjunction with autologous bone marrow after high‐dose chemotherapy in 69 patients with breast cancer or melanoma. The mean peripheral white… Expand
An update on GM-CSF and its potential role in melanoma management
TLDR
There is a strong rationale for GM-CSF as a vaccine adjuvant, but it appears of benefit only for strategies that directly involve DCs, such as intratumor talimogene laherparepvec and vaccines in which DCs are loaded with antigen ex vivo and injected admixed with GM- CSF. Expand
Optimization of Buffer Additives for Efficient Recovery of hGM-CSF from Inclusion Bodies Using Response Surface Methodology
TLDR
The approach developed in this work can be important to improve the refolding of other proteins with similar structural features to improve recovery of biologically active hGM-CSF from inclusion bodies. Expand
A Novel Methanol-Free Platform for Extracellular Expression of rhGM-CSF in Pichia pastoris
TLDR
The novel methanol independent PFMD expression platform would be a suitable candidate for driving heterologous gene expression especially for the production of food-grade and therapeutically important recombinant proteins. Expand
Improving Immunotherapy Through Glycodesign
TLDR
How optimizing glycosylation through a variety of glycoengineering strategies provides enticing opportunities to not only avoid past pitfalls, but also to substantially improve immunotherapies including antibodies and recombinant proteins, and cell-based therapies is described. Expand

References

SHOWING 1-10 OF 43 REFERENCES
Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer.
High-dose therapy with autologous marrow support results in durable complete remissions in selected patients with relapsed lymphoma and leukemia who cannot be cured with conventional dose therapy.Expand
Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin.
TLDR
It is reported that after standard-dose chemotherapy-induced bone marrow hypoplasia, IL-3 plus GM-CSF can be used to recruit PBPC, which might shorten the hematopoietic recovery after high- dose chemotherapy in chemosensitive lymphomas or solid tumors. Expand
Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor.
TLDR
Peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor lead to rapid hematopoietic recovery after myeloablative chemotherapy, and no graft failures have been observed with a follow-up of 4 to 12 months. Expand
Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.
TLDR
The use of CSF-primed PBPC can significantly improve hematopoietic recovery after high-dose chemotherapy and autologous BM support and was associated with a significant reduction in hospital resource utilization, and a reduction inhospital charges. Expand
Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy
The haematopoietic growth factor (HGF), granulocyte colony stimulating factor (G-CSF; filgrastim) substantially shortens the period of severe neutropenia that follows high-dose chemotherapy andExpand
GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR TO HARVEST CIRCULATING HAEMOPOIETIC STEM CELLS FOR AUTOTRANSPLANTATION
TLDR
The rapid haematological recovery made possible by this approach promises to increase the therapeutic index of high-dose chemoradiotherapy regimens and to widen their role as treatment for chemoradiosensitive tumours. Expand
Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma.
TLDR
Administration of GM-CSF after autologous hemopoietic stem cell transplantation in patients with lymphoma resulted in accelerated myeloid recovery, particularly in patients who received peripheral blood stem cells and nonpurged bone marrow, and was associated with a decreased incidence of bacterial infections. Expand
Granulocyte-macrophage colony-stimulating factor (GM-CSF): preclinical and clinical investigations.
In conclusion, hematopoietic growth factors have been shown to enhance the recovery and function of circulating WBCs after standard-dose cancer therapy or high-dose cancer therapy with ABMT, andExpand
Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease.
  • K. Taylor, S. Jagannath, +6 authors L. Souza
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1989
TLDR
RhG-CSF hastens granulocyte recovery after high-dose chemotherapy with ABMT in patients with relapsed/refractory Hodgkin's disease without significant toxicity. Expand
Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF.
TLDR
The data demonstrate that rapid and complete engraftment can be achieved following myeloablative conditioning therapy with rhG-CSF-exposed blood stem cells without the need for additional bone marrow support or growth factor administration posttransplantation. Expand
...
1
2
3
4
5
...